BRAF V600E in advanced NSCLC (≈1-2% of adenocarcinomas): dabrafenib + trametinib gives OR...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | dabrafenib + trametinib, encorafenib + binimetinib |
| Contraindicated monotherapy | vemurafenib monotherapy (lower ORR ~42%, no FDA NSCLC label, used only when MEKi unavailable) |
| Evidence summary | BRAF V600E in advanced NSCLC (≈1-2% of adenocarcinomas): dabrafenib + trametinib gives ORR ~64% in 1L (Planchard et al. Lancet Oncol 2017) and is FDA/EMA-approved across lines. Encorafenib + binimetinib (PHAROS, Riely et al. JCO 2023) ORR 75% in treatment-naïve, 46% pretreated — also FDA-approved 2023. |
Notes
ESCAT IA. OncoKB Level 1. Reflex testing for BRAF V600E in metastatic non-squamous NSCLC mandatory. Class 2 (V600 non-E) and Class 3 (kinase-impaired) BRAF mutations are NOT covered by these approvals — see separate cells. ICI monotherapy generally less effective in BRAF V600E NSCLC than BRAF/MEKi at progression.
Used By
No reverse references found in the YAML corpus.